In many neurologic diagnoses, significant interindividual variability exists in the outcomes of rehabilitation. One factor that may impact response to rehabilitation interventions is genetic variation. Genetic variation refers to the presence of differences in the DNA sequence among individuals in a population. Genetic polymorphisms are variations that occur relatively commonly and, while not disease-causing, can impact the function of biological systems. The purpose of this article is to describe genetic polymorphisms that may impact neuroplasticity, motor learning, and recovery after stroke.
Genetic polymorphisms for brain-derived neurotrophic factor (BDNF), dopamine, and apolipoprotein E have been shown to impact neuroplasticity and motor learning. Rehabilitation interventions that rely on the molecular and cellular pathways of these factors may be impacted by the presence of the polymorphism. For example, it has been hypothesized that individuals with the BDNF polymorphism may show a decreased response to neuroplasticity-based interventions, decreased rate of learning, and overall less recovery after stroke. However, research to date has been limited and additional work is needed to fully understand the role of genetic variation in learning and recovery.
Genetic polymorphisms should be considered as possible predictors or covariates in studies that investigate neuroplasticity, motor learning, or motor recovery after stroke. Future predictive models of stroke recovery will likely include a combination of genetic factors and other traditional factors (eg, age, lesion type, corticospinal tract integrity) to determine an individual's expected response to a specific rehabilitation intervention.
Physical Therapy Program (J.C.S.), Department of Exercise Science, University of South Carolina, Columbia; and Departments of Neurology, Anatomy & Neurobiology, and Physical Medicine & Rehabilitation (S.C.C.), University of California, Irvine.
Correspondence: Jill Campbell Stewart, PT, PhD, Physical Therapy Program, Department of Exercise Science, University of South Carolina, 921 Assembly St, Room 301D, Columbia, SC 29208 (email@example.com).
The content of this article was presented as part of the IV STEP Conference in Columbus, Ohio, in July 2016.
This work was supported by grants National Institutes of Health (NIH) R03 HD087481 and American Heart Association 15SDG24970011 to J.C.S. and NIH K24 HD074722 to S.C.C.
Steven C. Cramer has served as a consultant for MicroTransponder, Dart Neuroscience, and Roche. Jill Campbell Stewart declares no conflict of interest.